"Bruising and bleeding become more prevalent, and healing becomes more difficult," said Dr Tirathram Kaushik consultant Oncosurgeon, Wockhardt Hospitals Mira Road
Several parts of India have been reporting a high number of influenza cases in the last two months with prolonged illness and lingering cough. After battling two years of Covid pandemic, the rise in cases has created a scare among the general public.
Tamil Nadu s first SARS-CoV-2 antibody cocktail treatment for COVID-19 begins at Kauvery Hospital ANI | Updated: May 28, 2021 18:14 IST
Chennai (Tamil Nadu) [India], May 28 (ANI/NewsVoir): A new entrant into the treatment portfolio of COVID-19 in India is the cocktail formulation of Mono Clonal Antibodies (MCAb).
This treatment is offered to patients early in the evolution of COVID, in the phase of active multiplication of the virus in the body. That is invariably within ten days of the onset of the earliest symptoms of COVID-19. This timely intervention can reduce or even avoid the need for hospitalization by 70 percent.
Kauvery Hospital, one of the leading healthcare chains in Tamil Nadu, has kick started the antibody cocktail treatment. A COVID-19 patient with mild symptoms has already been the first to receive this treatment. The individual was cancer patient with newly diagnosed of early onset of renal failure, and therefore at high ris
Hospital begins monoclonal antibody treatment
Updated:
Updated:
Drug is said to bring down hospitalisation by 70%
Share Article
Drug is said to bring down hospitalisation by 70%
Kauvery Hospital in Chennai has treated a mildly symptomatic but high-risk COVID-19 patient with the monoclonal antibody cocktail that has been approved for emergency use in India. A statement issued by the hospital claimed that this was the first time the treatment had been used by a hospital in Tamil Nadu.
The individual was a cancer patient, who was recently diagnosed with early onset of renal failure, and hence was at higher risk of developing severe complications due to COVID-19.